Ocugen shares are trading higher Friday after the company announced it has received approval to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of its Phase 1/2 study. Ocugen said the Data and Safety Monitoring Board for the Phase 1/2 ArMaDa clinical trial for OCU410 has approved to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of the study.
Aurora Cannabis shares have gained nearly 150% over the past month as cannabis stocks continue to rally on a slate of positive developments in the sector. Earlier this month, Germany legalized cannabis and investors are hopeful that the DEA is leaning toward rescheduling marijuana in the U.S. On Monday, the Florida Supreme Court ruled to allow an initiative on the state's ballot in November which would legalize adult-use cannabis if approved by 60% of voters.
Kura Sushi reports quarterly losses of 9 cents per share, missing the analyst estimate of losses of 3 cents per share. Quarterly sales came in at $57.29 million, beating the $56.64 million analyst consensus estimate.